Lantern Pharma Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Lantern Pharma Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.12M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($20.78M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($15.96M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($14.26M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($12.36M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($5.91M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($2.43M) | Mar 10, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.98M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($22.22M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($17.88M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($14.43M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($12.59M) | Mar 20, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.51M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $16.13M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $11.89M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $8.60M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $7.57M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $2.24M | Mar 10, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.68M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($17.81M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($14.35M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($12.77M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($10.59M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($5.65M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($2.13M) | Mar 10, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.7K | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $12.6K | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $18.7K | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $27.8K | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $15.5K | Mar 20, 2023 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.04M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $25.57M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $43.65M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $58.84M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $73.95M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $20.36M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $1.43M | Mar 10, 2021 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.50M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $4.38M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $2.74M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $2.80M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $2.38M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $660.8K | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $489.3K | Mar 10, 2021 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.53M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $21.19M | Mar 30, 2026 |
| FY2025 | Dec 31, 2023 | $40.91M | Mar 30, 2026 |
| FY2024 | Dec 31, 2022 | $56.04M | Mar 27, 2025 |
| FY2023 | Dec 31, 2021 | $71.57M | Mar 18, 2024 |
| FY2022 | Dec 31, 2020 | $19.70M | Mar 20, 2023 |
| FY2021 | Dec 31, 2019 | $943.3K | Mar 10, 2022 |
| FY2020 | Dec 31, 2018 | ($201.8K) | Mar 10, 2021 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($93.15M) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | ($76.03M) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | ($55.24M) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | ($39.28M) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | ($25.02M) | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | ($12.66M) | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | ($6.75M) | Mar 10, 2021 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.42M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | $7.51M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | $21.94M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | $37.20M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | $51.52M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | $19.23M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | $1.23M | Mar 10, 2021 |
| FY2020 | Dec 31, 2018 | $445.2K | Mar 10, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 20, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | (1) | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 18, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 11.25M | Mar 30, 2026 |
| FY2025 | Dec 31, 2024 | 10.78M | Mar 30, 2026 |
| FY2024 | Dec 31, 2023 | 10.72M | Mar 27, 2025 |
| FY2023 | Dec 31, 2022 | 10.86M | Mar 18, 2024 |
| FY2022 | Dec 31, 2021 | 11.09M | Mar 20, 2023 |
| FY2021 | Dec 31, 2020 | 6.22M | Mar 10, 2022 |
| FY2020 | Dec 31, 2019 | 1.98M | Mar 10, 2021 |